Akut mieloid leukémia (AML): vizsgálatok itt: Kína
226 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleBugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Shenzhen
- Életkor
- 18 év to 70 év
- People
- 10
- Run by
- Shenzhen University General Hospital
See details and how to joinNCT07563179 - 1. fázisTaking peopleCD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 25
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06696846 - 1/2. fázisTaking peopleStudy of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
- Where
- Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 682
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT04501120 - 3. fázisTaking peopleHEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
- Where
- Hanzhou
- Életkor
- 18 év and over
- People
- 324
- Run by
- Sunshine Lake Pharma Co., Ltd.
See details and how to joinNCT05586074 - 2. fázisTaking peopleStudy on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
- Where
- Suzhou
- Életkor
- 15 év to 65 év
- People
- 48
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT06816134 - 2/3. fázisCsak meghívásosVEN+IDAC vs IDAC in AML
- Where
- Guangzhou
- Életkor
- 18 év to 65 év
- People
- 232
- Run by
- Guangdong Second Provincial General Hospital
See details and how to joinNCT07537257 - No phaseTaking peopleLeukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
- Where
- Beijing
- Életkor
- 6 év to 60 év
- People
- 210
- Run by
- Peking University People's Hospital
See details and how to joinNCT07537738 - No phaseTaking peopleThe Efficacy of Allo-HSCT in ND HR-CBF-AML
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 90
- Run by
- Ruijin Hospital
See details and how to joinNCT06458244 - No phaseTaking peopleA Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
- Where
- Suzhou
- Életkor
- 50 év and over
- People
- 30
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07500753 - 3. fázisNot yet taking people in KínaVAH vs VA in Newly Diagnosed Elderly AML
- Where
- Shanghai
- Életkor
- 60 év to 75 év
- People
- 308
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07469046 - 1/2. fázisTaking peopleAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
- Where
- Shenzhen
- Életkor
- 18 év to 75 év
- People
- 96
- Run by
- Beijing Biotech
See details and how to joinNCT07523555 - No phaseNot yet taking people in KínaABC Maintenance Therapy for AML
- Where
- Wuhan
- Életkor
- 18 év to 80 év
- People
- 104
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07521124 - 2. fázisTaking peopleVA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 48
- Run by
- Beijing 302 Hospital
See details and how to joinNCT07514832 - 2. fázisTaking peopleVenetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia
- Where
- Beijing
- Életkor
- 14 év to 60 év
- People
- 204
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT07512700 - 2. fázisTaking peopleClinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Beijing
- Életkor
- 14 év to 75 év
- People
- 200
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT06084819 - 2. fázisNot yet taking people in KínaExploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 61
- Run by
- First People's Hospital of Hangzhou
See details and how to joinNCT07507825 - 2. fázisNot yet taking people in KínaEfficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 35
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07505160 - No phaseTaking peopleDigital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
- Where
- Beijing
- People
- 100
- Run by
- Peking University People's Hospital
See details and how to joinNCT07500441 - 4. fázisTaking peopleRuxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
- Where
- Beijing
- Életkor
- 14 év to 75 év
- People
- 200
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT07101588 - 3. fázisTaking peopleMRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
- Where
- Shanghai, Suzhou
- Életkor
- 14 év to 70 év
- People
- 594
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07463651 - 3. fázisNot yet taking people in KínaVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
- Where
- Changzhou, Hangzhou, Hefei, Huai'an, Jinan, Jingjiang, Lianyungang, Luoyang, Nanjing, Nantong, Ningbo, Suzhou, Wuhan, Wuxi, Yancheng, Yangzhou
- Életkor
- 18 év to 65 év
- People
- 204
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07486479 - 1/2. fázisNot yet taking people in KínaAclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 112
- Run by
- Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07486726 - 2. fázisTaking peopleVAC Regimen for AML Patients Who Failed to Response to VA Regimen
- Where
- Suzhou
- Életkor
- 18 év to 80 év
- People
- 32
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT06220162 - No phaseNot yet taking people in KínaHEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
- Where
- Hangzhou, Ningbo
- Életkor
- 1 év to 21 év
- People
- 400
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07483749 - 1/2. fázisTaking peopleVenetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 29
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07451912